Tomaszewska, Agnieszka, Jagasia, Madan, Beohou, Eric, van der Werf, Steffie, Blaise, Didier, Kanfer, Edward, Milpied, Noel, Remenyi, Peter, Ciceri, Fabio, Bourhis, Jean H., Chevallier, Patrice, Solano, Carlos, Socie, Gerard, Bruno, Benedetto, Rambaldi, Alessandro, Castagna, Luca ORCID: 0000-0002-6239-7387, Kroger, Nicolaus ORCID: 0000-0001-5103-9966, Corradini, Paolo, Afanasyev, Boris, Ladetto, Marco, Niederwieser, Dietger, Scheid, Christof, Sengeloev, Henrik, Kroschinsky, Frank, Yakoub-Agha, Ibrahim, Schoemans, Helene, Koenecke, Christian, Penack, Olaf ORCID: 0000-0003-4876-802X, Peric, Zinaida, Greinix, Hildegard, Duarte, Rafael F. and Basak, Grzegorz W. (2021). Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. Front. Immunol., 11. LAUSANNE: FRONTIERS MEDIA SA. ISSN 1664-3224

Full text not available from this repository.

Abstract

Rituximab (R) is increasingly incorporated in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in patients with B-cell malignancies, not only to improve disease control, but also to prevent graft-versus-host disease (GVHD). There are no randomized prospective data to validate this practice, although single center data and the CIBMTR analysis have shown promising results. We aimed at validation of these findings in a large registry study. We conducted a retrospective analysis using the EBMT registry of 3,803 adult patients with B-cell malignancies undergoing alloHCT (2001-2013) with either rituximab (R-RIC-9%) or non-rituximab (RIC-91%) reduced intensity regimens respectively. Median age and median follow up were 55 years (range 19.1-77.3) and 43.2 months (range 0.3-179.8), respectively. There was no difference in transplant outcomes (R-RIC vs RIC), including 1-year overall survival (69.9% vs 70.7%), 1-year disease-free survival (64.4% vs 62.2%), 1-year non-relapse mortality (21% vs 22%), and day-100 incidence of acute GVHD 2-4 degrees (12% vs 12%). In summary, we found that addition of rituximab in RIC regimens for B-cell malignancies had no significant impact on major transplant outcome variables. Of note, data on chronic GVHD was not available, limiting the conclusions that can be drawn from the present study.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Tomaszewska, AgnieszkaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jagasia, MadanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Beohou, EricUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
van der Werf, SteffieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Blaise, DidierUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kanfer, EdwardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Milpied, NoelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Remenyi, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ciceri, FabioUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bourhis, Jean H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Chevallier, PatriceUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Solano, CarlosUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Socie, GerardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bruno, BenedettoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rambaldi, AlessandroUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Castagna, LucaUNSPECIFIEDorcid.org/0000-0002-6239-7387UNSPECIFIED
Kroger, NicolausUNSPECIFIEDorcid.org/0000-0001-5103-9966UNSPECIFIED
Corradini, PaoloUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Afanasyev, BorisUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ladetto, MarcoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Niederwieser, DietgerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheid, ChristofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sengeloev, HenrikUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kroschinsky, FrankUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Yakoub-Agha, IbrahimUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schoemans, HeleneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Koenecke, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Penack, OlafUNSPECIFIEDorcid.org/0000-0003-4876-802XUNSPECIFIED
Peric, ZinaidaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Greinix, HildegardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Duarte, Rafael F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Basak, Grzegorz W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-607554
DOI: 10.3389/fimmu.2020.613954
Journal or Publication Title: Front. Immunol.
Volume: 11
Date: 2021
Publisher: FRONTIERS MEDIA SA
Place of Publication: LAUSANNE
ISSN: 1664-3224
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
VERSUS-HOST-DISEASEMultiple languages
ImmunologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60755

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item